ライフサイエンスコーパス: sulfamethoxazole

1 rmetoprim-sulfadimethoxine, and trimethoprim-sulfamethoxazole).

2 ed benefit with co-trimoxazole (trimethoprim-sulfamethoxazole).

3 7% to clindamycin, and 21.6% to trimethoprim-sulfamethoxazole.

4 m, linezolid, moxifloxacin, and trimethoprim-sulfamethoxazole.

5 n, clindamycin, gentamicin, and trimethoprim-sulfamethoxazole.

6 d dicloxacillin, but not abacavir or nitroso sulfamethoxazole.

7 amycin, gentamicin sulfate, and trimethoprim-sulfamethoxazole.

8 ine, tigecycline, rifampin, and trimethoprim/sulfamethoxazole.

9 MICs of trimethoprim-sulfamethoxazole and/or sulfamethoxazole.

10 r PcP with a combination of trimethoprim and sulfamethoxazole.

11 -trimoxazole, a cocktail of trimethoprim and sulfamethoxazole.

12 except for chloramphenicol and trimethoprim-sulfamethoxazole.

13 sting 567 staphylococci against trimethoprim-sulfamethoxazole.

14 eceived antibiotic therapy with trimethoprim-sulfamethoxazole.

15 ent course of ciprofloxacin and trimethoprim-sulfamethoxazole.

16 espite anti-Pc prophylaxis with trimethoprim-sulfamethoxazole.

17 erythromycin, tetracycline, and trimethoprim-sulfamethoxazole.

18 infants also received high-dose trimethoprim-sulfamethoxazole.

19 oroquinolones, penicillins, and trimethoprim-sulfamethoxazole.

20 cin, rifampin, minocycline, and trimethoprim-sulfamethoxazole.

21 profloxacin, gentamicin, and/or trimethoprim-sulfamethoxazole.

22 nd 57 (82.6%) were resistant to trimethoprim-sulfamethoxazole.

23 ith amoxicillin, flucloxacillin, and nitroso-sulfamethoxazole.

24 or macrolide antibiotic, or for trimethoprim-sulfamethoxazole.

25 hfr, which confer resistance to trimethoprim-sulfamethoxazole.

26 and only 7% were susceptible to trimethoprim-sulfamethoxazole.

27 h ampicillin, trimethoprim, and trimethoprim-sulfamethoxazole.

28 coli strains with resistance to trimethoprim-sulfamethoxazole.

29 in all 19 patients treated with trimethoprim-sulfamethoxazole.

30 es 19A and 23F was resistant to trimethoprim-sulfamethoxazole.

31 oramphenicol, erythromycin, and trimethoprim-sulfamethoxazole.

32 postdischarge prophylaxis with trimethoprim-sulfamethoxazole.

33 postdischarge prophylaxis with trimethoprim-sulfamethoxazole.

34 rpreted based on human data for trimethoprim-sulfamethoxazole.

35 concern were performed with bisphenol A and sulfamethoxazole.

36 ate resistance was detected for trimethoprim-sulfamethoxazole (10 strains) and clindamycin (3 strains

37 Trimethoprim-sulfamethoxazole (160/800 mg twice daily for 3 days), ni

38 ser extent, to kanamycin (19%), trimethoprim-sulfamethoxazole (17%), and gentamicin (11%).

39 <0.1-1.4 days), bezafibrate (<0.1-4.8 days), sulfamethoxazole (2-33 days), naproxen (6-19 days), carb

40 me antibiotics in drinking waters, including sulfamethoxazole (3.0-3.4 ng/L), macrolides (1.4-4.9 ng/

41 xin, 500 mg 4 times daily, plus trimethoprim-sulfamethoxazole, 320 mg/1600 mg twice daily, for 7 days

42 prescribed, only ofloxacin (1 ng.L(-1)) and sulfamethoxazole (4 ng.L(-1)) persisted in the river.

43 olates that were susceptible to trimethoprim-sulfamethoxazole (4 percent, P<0.001).

44 mpicillin, chloramphenicol, and trimethoprim-sulfamethoxazole; 4 were also resistant to nalidixic aci

45 /kg/day) or SXT (trimethoprim 10 mg/kg/day + sulfamethoxazole 50 mg/kg/day) orally for 7 days for UFI

46 ant to fluoroquinolones (100%), trimethoprim-sulfamethoxazole (55%), and tetracycline (53%).

47 isolates displayed resistance most often to sulfamethoxazole (57%), streptomycin (56%), tetracycline

48 (92%), and sulfamethoxazole or trimethoprim-sulfamethoxazole (70%).

49 to penicillin, macrolides, and trimethoprim-sulfamethoxazole, 8 had other resistance patterns, and 3

50 3.9%), clindamycin (65.5%), and trimethoprim-sulfamethoxazole (80%); however, categorical concordance

51 ully treated in all cases using trimethoprim-sulfamethoxazole (800 mg/160 mg) twice daily for 45 days

52 st removal of OMPs (removal of 92 +/- 3% for sulfamethoxazole, 84 +/- 3% for naproxen, 82 +/- 3% for

53 amycin, 73%; levofloxacin, 73%; trimethoprim-sulfamethoxazole, 9%; and daptomycin, 9%.

54 solabial, and hand samples, whereas N-acetyl-sulfamethoxazole, a drug metabolite, was detected in axi

55 tewater borne MPs diclofenac, carbamazepine, sulfamethoxazole, acesulfame, sucralose, benzotriazole,

56 in the IAST-EBC successfully modeled MIB and sulfamethoxazole adsorption by three different PACs in t

57 ting a protocolized approach to trimethoprim-sulfamethoxazole adverse drug reaction assessment and re

58 Forty-two patients (35%) had 48 trimethoprim-sulfamethoxazole adverse drug reactions documented eithe

59 ared with standard prophylaxis (trimethoprim-sulfamethoxazole alone).

60 ine synthesis with the folic acid antagonist sulfamethoxazole also inhibited spreading.

61 ted by increasing resistance to trimethoprim-sulfamethoxazole, amoxicillin/clavulanic acid, and cipro

62 d high MICs of >4/76 mug/ml for trimethoprim-sulfamethoxazole, an antibiotic commonly used to treat u

63 For sulfamethoxazole, an antibiotic that is frequently detec

64 cin among S. pneumoniae and for trimethoprim/sulfamethoxazole and azithromycin among H. influenzae.

65 e predicted no-effect levels for diclofenac, sulfamethoxazole and carbamazepine, respectively.

66 recalcitrant contaminants such as sucralose, sulfamethoxazole and carbamazepine, which are typical wa

67 all strains were susceptible to trimethoprim-sulfamethoxazole and ciprofloxacin.

68 for all isolates), followed by trimethoprim-sulfamethoxazole and ciprofloxacin.

69 tigation of metabolism-dependent toxicity of sulfamethoxazole and dapsone, and subsequent incubation

70 n of delayed-type hypersensitivity caused by sulfamethoxazole and dapsone.

71 With trimethoprim-sulfamethoxazole and fluoroquinolones, the drug-bug mism

72 enem, gentamicin, amikacin, and trimethoprim-sulfamethoxazole and had reduced susceptibilities to cef

73 etch of the Simeto River, whereas sucralose, sulfamethoxazole and ibuprofen have always been well cor

74 0%) and 6 of 47 (12.80%) in the trimethoprim-sulfamethoxazole and placebo groups, respectively (P = .

75 y treatment with the antibiotic trimethoprim-sulfamethoxazole and possibly by coinfection with P. aer

76 tenolol, metoprolol, and trimethoprim, while sulfamethoxazole and propranolol were attenuated mainly

77 te constants of two sulfonamide antibiotics (sulfamethoxazole and sulfadiazine) in the presence of un

78 rpretation of in vitro MICs for trimethoprim-sulfamethoxazole and sulfamethoxazole and the lack of qu

79 o MICs for trimethoprim-sulfamethoxazole and sulfamethoxazole and the lack of quality controls for No

80 Additional prophylaxis included trimethoprim-sulfamethoxazole and valganciclovir.

81 to ampicillin, gentamicin, and trimethoprim-sulfamethoxazole and with susceptibility to fluoroquinol

82 UMCR1 was only resistant to sulfamethoxazole and, like other S. aureus isolates, pol

83 found to have resistant MICs of trimethoprim-sulfamethoxazole and/or sulfamethoxazole.

84 a single breakpoint for testing trimethoprim-sulfamethoxazole and/or trimethoprim-sulfadiazine with S

85 lfamethoxazole beta-D-glucuronide, 4-nitroso sulfamethoxazole, and 4-nitro sulfamethoxazole were irra

86 es, 100 percent to rifampin and trimethoprim-sulfamethoxazole, and 92 percent to tetracycline.

87 in resistance to ciprofloxacin, trimethoprim-sulfamethoxazole, and ampicillin in community-acquired u

88 trated on the pharmaceuticals acetaminophen, sulfamethoxazole, and carbamazepine and on the pharmaceu

89 susceptibility to tetracycline, trimethoprim-sulfamethoxazole, and chloramphenicol was observed.

90 crobials: namely, azithromycin, trimethoprim-sulfamethoxazole, and ciprofloxacin.

91 en who received bed nets, daily trimethoprim-sulfamethoxazole, and combination antiretroviral therapy

92 h HIV receiving bed nets, daily trimethoprim-sulfamethoxazole, and combination antiretroviral therapy

93 ofur, erythromycin, tilmicosin, trimethoprim-sulfamethoxazole, and florfenicol, with some minor varia

94 s but susceptible to aztreonam, trimethoprim-sulfamethoxazole, and fluoroquinolones.

95 isolates were susceptible to ciprofloxacin, sulfamethoxazole, and linezolid and susceptible or inter

96 ol A), three pharmaceuticals (carbamazepine, sulfamethoxazole, and meprobamate), and the caffeine deg

97 herapy consisted of tacrolimus, trimethoprim/sulfamethoxazole, and prednisone (the latter two were di

98 lly susceptible to clindamycin, trimethoprim-sulfamethoxazole, and rifampin, but inducible macrolide-

99 ptible in vitro to clindamycin, trimethoprim-sulfamethoxazole, and rifampin.

100 es, macrolides, quinolones, trimethoprim and sulfamethoxazole, and rifampin.

101 emfibrozil, ibuprofen, ketoprofen, naproxen, sulfamethoxazole, and sildenafil).

102 o ampicillin, chloramphenicol, streptomycin, sulfamethoxazole, and tetracycline (the AmCmStSuTe pheno

103 ance to ampicillin, kanamycin, streptomycin, sulfamethoxazole, and tetracycline (the AmKmStSuTe pheno

104 ance to ampicillin, kanamycin, streptomycin, sulfamethoxazole, and tetracycline and to ampicillin, ch

105 inopenicillin, fluoroquinolone, trimethoprim/sulfamethoxazole, and tetracycline usage on resistance o

106 o ampicillin, chloramphenicol, streptomycin, sulfamethoxazole, and tetracycline, respectively.

107 cillin, rifampin, tetracycline, trimethoprim-sulfamethoxazole, and vancomycin.

108 llin (PEN), tetracycline (TET), trimethoprim-sulfamethoxazole, and vancomycin.

109 penicillins, tetracycline, and trimethoprim-sulfamethoxazole are good treatment options.

110 th S. equi This study indicates trimethoprim-sulfamethoxazole as an acceptable surrogate for trimetho

111 fornia cohort were resistant to trimethoprim-sulfamethoxazole as well as other antibiotics.

112 epartments to determine whether trimethoprim-sulfamethoxazole (at doses of 320 mg and 1600 mg, respec

113 All investigated metabolites, except sulfamethoxazole beta-D-glucuronide were found to be mor

114 SMX, N-acetyl sulfamethoxazole, sulfamethoxazole beta-D-glucuronide, 4-nitroso sulfameth

115 may enhance antibiotic removal, as shown for sulfamethoxazole; (c) not accounting for fractions sorbe

116 egradation of six representative OMPs (i.e., sulfamethoxazole, carbamazepine, tylosin, atrazine, napr

117 in, tetracycline, streptomycin, trimethoprim-sulfamethoxazole, chloramphenicol, and gentamicin.

118 Trimethoprim-sulfamethoxazole, ciprofloxacin, and piperacillin-tazoba

119 lowing agents: chloramphenicol, trimethoprim-sulfamethoxazole, ciprofloxacin, and rifampin.

120 d removal efficiencies of three antibiotics (sulfamethoxazole, ciprofloxacin, tetracycline) in pilot-

121 ciprofloxacin, gentamicin, trimethoprim and sulfamethoxazole, clarithromycin, and azithromycin.

122 ycin followed by 1 week of oral trimethoprim-sulfamethoxazole combination therapy.

123 tis, the use of cephalexin plus trimethoprim-sulfamethoxazole compared to cephalexin alone did not re

124 oramphenicol, and 93 (92.1%) to trimethoprim-sulfamethoxazole compared with 22 (62.9%), 15 (39.4%), a

125 ntiretroviral therapy or use of trimethoprim-sulfamethoxazole did not impact the risk of MRSA carriag

126 In 36%, trimethoprim-sulfamethoxazole dosage was elevated by current ESRD gui

127 53 days), trimethoprim (DT(50) = 3 days) and sulfamethoxazole (DT(50) = 1 days).

128 fected cells with retinoic acid and dimethyl sulfamethoxazole enhanced their microbicidal effects.

129 ive bacilli-but mostly not EPE (trimethoprim-sulfamethoxazole, fluoroquinolones, oral cephalosporins,

130 lids biochar, and coal-derived PAC to remove sulfamethoxazole from wastewater.

131 isolates that were resistant to trimethoprim-sulfamethoxazole from women with community-acquired urin

132 11 percent to 16 percent), and trimethoprim-sulfamethoxazole (from 25 percent to 29 percent).

133 erence favoring cephalexin plus trimethoprim-sulfamethoxazole, further research may be needed.

134 luding ampicillin, ceftazidime, trimethoprim-sulfamethoxazole, gentamicin, and ciprofloxacin) reporte

135 ofloxacin, rifampin, vancomycin, ampicillin, sulfamethoxazole, gentamicin, or metronidazole).

136 it for 428 children (214 in the trimethoprim-sulfamethoxazole group and 214 in the placebo group).

137 524 participants (0.4%) in the trimethoprim-sulfamethoxazole group and in 2 of 533 participants (0.4

138 Weight gain in the trimethoprim-sulfamethoxazole group and the placebo group was similar

139 630 participants (80.5%) in the trimethoprim-sulfamethoxazole group versus 454 of 617 participants (7

140 524 participants (92.9%) in the trimethoprim-sulfamethoxazole group versus 457 of 533 participants (8

141 icipants in the cephalexin plus trimethoprim-sulfamethoxazole group vs 165 (85.5%) of 193 in the ceph

142 icipants in the cephalexin plus trimethoprim-sulfamethoxazole group vs 171 (69.0%) of 248 in the ceph

143 in 1 participant (0.2%) in the trimethoprim-sulfamethoxazole group.

144 s were resistant to the cytotoxic effects of sulfamethoxazole hydroxylamine but not dapsone hydroxyla

145 zole in 21.7% of strains and to trimethoprim-sulfamethoxazole in 21.0% resulted from polymorphisms of

146 ctrometry, and it was demonstrated to screen sulfamethoxazole in a complex matrix such as seawater, w

147 d-pyridoxine (coformulated with trimethoprim-sulfamethoxazole in a single fixed-dose combination tabl

148 cin, doxycycline, imipenem, and trimethoprim-sulfamethoxazole in each of four laboratories.

149 Resistance to trimethoprim-sulfamethoxazole in Iran is low and this drug should be

150 Sulfamethoxazole in particular had a stimulatory effect

151 rmation rates increased for trimethoprim and sulfamethoxazole in the dark, when microbial respiration

152 or atenolol, carbamazepine, propranolol, and sulfamethoxazole in wetland water under representative c

153 While trimethoprim-sulfamethoxazole is considered first-line therapy for Pn

154 of Pneumocystis pneumonia with trimethoprim/sulfamethoxazole is effective in reducing this risk.

155 Trimethoprim-sulfamethoxazole is the preferred drug regimen for both

156 e suspension (8 mg trimethoprim/kg and 40 mg sulfamethoxazole/kg/day) for 5 days in 14 control cluste

157 exposure, and in the absence of trimethoprim-sulfamethoxazole, lumefantrine exposure is a determinant

158 we demonstrated that (a) the elimination of sulfamethoxazole may be significantly underestimated whe

159 mpicillin, chloramphenicol, and trimethoprim-sulfamethoxazole (multidrug resistant [MDR]) was limited

160 mpicillin, chloramphenicol, and trimethoprim-sulfamethoxazole (multidrug-resistant [MDR]).

161 mpicillin, chloramphenicol, and trimethoprim-sulfamethoxazole (multidrug-resistant S. Typhi [MDRST]);

162 mpicillin, chloramphenicol, and trimethoprim-sulfamethoxazole (multidrug-resistant Salmonella Typhi [

163 or >/=40% (beta-lactams), >50% (trimethoprim-sulfamethoxazole , multidrug), or >70% (ciprofloxacin, g

164 (n = 11), nevirapine (n = 14), trimethoprim-sulfamethoxazole (n = 11), dapsone (n = 4), allopurinol

165 iate antimicrobial therapy with trimethoprim-sulfamethoxazole, nitrofurantoin, or fosfomycin is indic

166 CI), 0.60-0.97; P =.03; risk of trimethoprim-sulfamethoxazole nonsusceptibility was also lower in the

167 Trimethoprim-sulfamethoxazole or methotrexate may be valuable in sele

168 Trimethoprim-sulfamethoxazole or placebo taken orally, once daily, fo

169 ionally, each was randomized to trimethoprim-sulfamethoxazole or placebo.

170 0%), rifabutin (100%), ethambutol (92%), and sulfamethoxazole or trimethoprim-sulfamethoxazole (70%).

171 nd less frequently resistant to trimethoprim-sulfamethoxazole (OR = 0.38; 95% CI = 0.18 to 0.80; P =

172 reated with other beta-lactams, trimethoprim-sulfamethoxazole, or vancomycin.

173 ght <5 kg), or 40 mg trimethoprim and 200 mg sulfamethoxazole orally (age >6 months or bodyweight >5

174 ly regimens of 20 mg trimethoprim and 100 mg sulfamethoxazole orally (age <6 months or bodyweight <5

175 llin-clavulanic acid (P = .03), trimethoprim-sulfamethoxazole (P = .01), and ciprofloxacin (P = .03)

176 most common antimicrobials were trimethoprim-sulfamethoxazole, penicillin, and amoxicillin (22%, 8/37

177 , which consisted of continuous trimethoprim-sulfamethoxazole plus at least 12 weeks of isoniazid-pyr

178 Besides biotransformation (sulfamethoxazole), poor membrane permeability (cimetidin

179 erm treatment with combined trimethoprim and sulfamethoxazole prevented recurrent disease in patients

180 Trimethoprim-sulfamethoxazole promotes the excision of all, and cipro

181 s associated with no treatment, trimethoprim-sulfamethoxazole prophylaxis alone, antiretroviral thera

182 ical criteria, as compared with trimethoprim-sulfamethoxazole prophylaxis alone.

183 A strategy of trimethoprim-sulfamethoxazole prophylaxis and antiretroviral therapy,

184 Women received daily trimethoprim-sulfamethoxazole prophylaxis and insecticide-treated bed

185 was controlled after systematic trimethoprim-sulfamethoxazole prophylaxis in exposed patients.

186 n, we evaluated the efficacy of trimethoprim-sulfamethoxazole prophylaxis in preventing recurrences (

187 Trimethoprim/sulfamethoxazole prophylaxis was associated with a reduc

188 her cases were identified after trimethoprim-sulfamethoxazole prophylaxis was introduced in the entir

189 from a large clinical trial of trimethoprim-sulfamethoxazole prophylaxis, there was no evidence that

190 fective as those that also used trimethoprim-sulfamethoxazole prophylaxis.

191 Co-trimoxazole (fixed-dose trimethoprim-sulfamethoxazole) prophylaxis administered before antire

192 icantly more patients underwent trimethoprim-sulfamethoxazole rechallenge after protocol implementati

193 ction of a standard approach to trimethoprim-sulfamethoxazole rechallenge in the context of both prio

194 i pneumonia; the combination of trimethoprim-sulfamethoxazole remains the first-line agent for both t

195 p A), in 28 of 55 isolates with trimethoprim-sulfamethoxazole resistance (51 percent) and in 2 of 50

196 el significantly predicted both trimethoprim-sulfamethoxazole resistance (prevalence ratio, 2.7 [95%

197 etracycline resistance), and an unidentified sulfamethoxazole resistance allele.

198 It also carried the sul1 gene for sulfamethoxazole resistance and a 1-kb class I integron

199 sotype 2123 was associated with trimethoprim-sulfamethoxazole resistance and K1 (versus K5) capsule.

200 ized significant contributor to trimethoprim-sulfamethoxazole resistance in the United States.

201 ycin resistance (ICR) (n = 30), trimethoprim-sulfamethoxazole-resistant MRSA (n = 10), vancomycin-res

202 effect to increase and decrease with MIB and sulfamethoxazole, respectively.

203 re resistant to clindamycin and trimethoprim/sulfamethoxazole, respectively.

204 Cefprozil, cefaclor, and trimethoprim-sulfamethoxazole results differed the most, while result

205 Trimethoprim-sulfamethoxazole retains clinical efficacy, but resistan

206 0 h treatment, the total degradation rate of sulfamethoxazole (SMX) and norfloxacin (NOR) were 97.4 +

207 amethoxydiazine (SMD), sulfamethazine (SMT), sulfamethoxazole (SMX) and sulfadiazine (SDZ) in importe

208 ), ciprofloxacin (CIP), roxarsone (ROX), and sulfamethoxazole (SMX) antibiotics in agriculturally rel

209 Treatment with sulfamethoxazole (SMX) can lead to hypersensitivity reac

210 t increased susceptibility to the antibiotic sulfamethoxazole (SMX) compared with channels formed wit

211 ted (AC) or unacclimated (UAC) to historical sulfamethoxazole (SMX) contamination, and a laboratory-g

212 Carbon isotope fractionation of sulfamethoxazole (SMX) during biodegradation by Microbac

213 Sulfamethoxazole (SMX) is a veterinary antibiotic that i

214 he present study evaluated the metabolism of sulfamethoxazole (SMX), a commonly used sulfonamide anti

215 Sulfamethoxazole (SMX), a widely used antibiotic, has be

216 This concept has been applied to sulfamethoxazole (SMX), one of the many antibiotics used

217 lysis of human metabolites of the antibiotic sulfamethoxazole (SMX).

218 have used a T cell-priming assay and nitroso sulfamethoxazole (SMX-NO) as a model Ag to investigate t

219 se and solution of three sulphonamides (SAs; sulfamethoxazole, SMX; sulfamethazine, SMZ; and sulfadim

220 SMX, N-acetyl sulfamethoxazole, sulfamethoxazole beta-D-glucuronide, 4

221 th KRV and a combination of trimethoprim and sulfamethoxazole (Sulfatrim) beginning on the day of inf

222 ociated infections resistant to trimethoprim-sulfamethoxazole, sulfisoxazole, streptomycin, and furaz

223 rim-sulfamethoxazole (TMP-SMX), 355 (32%) to sulfamethoxazole-sulfisoxazole, 312 (28%) to tetracyclin

224 o ampicillin, chloramphenicol, streptomycin, sulfamethoxazole-sulfisoxazole, and tetracycline, includ

225 Azithromycin and trimethoprim-sulfamethoxazole (SXT) are widely used to treat undiffer

226 Ten days of trimethoprim-sulfamethoxazole (SXT) therapy reduces urinary recurrenc

227 Overall ciprofloxacin (CIP), trimethoprim-sulfamethoxazole (SXT), and cefazolin (CFZ) susceptibili

228 been described as resistant to trimethoprim-sulfamethoxazole (SXT), but the test medium may affect t

229 nts were randomized to Group 1 (trimethoprim/sulfamethoxazole tablet every 2 days) or Group 2 (identi

230 riasis ceased more rapidly with trimethoprim-sulfamethoxazole than with ciprofloxacin.

231 xpressed resistance only to streptomycin and sulfamethoxazole (the StSu phenotype; 8.3% of serovar Ty

232 With the exception of sulfamethoxazole, the apparent distribution coefficient

233 For 4-cyanoaniline and sulfamethoxazole, the DOM concentration dependence of th

234 However, for children receiving trimethoprim-sulfamethoxazole, the risk of recurrent parasitemia did

235 Trimethoprim/sulfamethoxazole therapy resulted in a 100% reduction in

236 followed by phosphomycin (23%), trimethoprim-sulfamethoxazole (TMP-SMX) (9%), and cefuroxime (7%).

237 Trimethoprim-sulfamethoxazole (TMP-SMX) and fluoroquinolones were act

238 Daily trimethoprim-sulfamethoxazole (TMP-SMX) and insecticide-treated nets

239 ntibiotic therapy included oral trimethoprim-sulfamethoxazole (TMP-SMX) and rifampin, TMP-SMX alone,

240 Clindamycin and trimethoprim-sulfamethoxazole (TMP-SMX) are commonly prescribed, but

241 o receive either clindamycin or trimethoprim-sulfamethoxazole (TMP-SMX) for 10 days.

242 least 10 days, followed by oral trimethoprim-sulfamethoxazole (TMP-SMX) for 12 to 20 weeks.

243 V protease inhibitors (PIs) and trimethoprim-sulfamethoxazole (TMP-SMX) have known activity against p

244 Trimethoprim-sulfamethoxazole (TMP-SMX) is widely used in malaria-end

245 xposed (n = 175) and prescribed trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis.

246 s, primarily in those receiving trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis.

247 ) to streptomycin, 402 (36%) to trimethoprim-sulfamethoxazole (TMP-SMX), 355 (32%) to sulfamethoxazol

248 es (43%) were nonsusceptible to trimethoprim-sulfamethoxazole (TMP-SMX), and all isolates were clinda

249 rofloxacin, imipenem, rifampin, trimethoprim-sulfamethoxazole (TMP-SMX), and vancomycin.

250 ssigned to receive clindamycin, trimethoprim-sulfamethoxazole (TMP-SMX), or placebo for 10 days.

251 en the increasing resistance to trimethoprim-sulfamethoxazole (TMP-SMX), the current drug of choice f

252 Additionally, trimethoprim-sulfamethoxazole (TMP-SMX), used for opportunistic infec

253 ract infections (UTI) caused by trimethoprim-sulfamethoxazole (TMP-SMX)-resistant Escherichia coli is

254 Trimethoprim-sulfamethoxazole (TMP-SMZ) and the fluoroquinolones have

255 Trimethoprim-sulfamethoxazole (TMP-SMZ) is an alternative treatment f

256 Trimethoprim-sulfamethoxazole (TMP-SMZ) is the most effective Pneumoc

257 lts, and many receive long-term trimethoprim-sulfamethoxazole (TMP-SMZ) prophylactic therapy.

258 sms is typically susceptible to trimethoprim-sulfamethoxazole (TMP-SMZ), and this therefore represent

259 The efficacy of trimethoprim-sulfamethoxazole (TMP/SMX) in the prevention of toxoplas

260 roviral therapy (ART) and daily trimethoprim-sulfamethoxazole (TMP/SXT).

261 doxycycline, sulfadiazine, and trimethoprim-sulfamethoxazole [TMP-SMX]) and abstracted data on mater

262 le antifolates such as Bactrim (trimethoprim-sulfamethoxazole; TMP-SMX) continue to play an important

263 ithout abscess, the addition of trimethoprim-sulfamethoxazole to cephalexin did not improve outcomes

264 acillin, amoxicillin, isoniazid, and nitroso-sulfamethoxazole) to characterize the proteins packaged

265 However, exosomes from nitroso-sulfamethoxazole-treated hepatocytes selectively package

266 ated patients and in 33% of 187 trimethoprim-sulfamethoxazole-treated patients, respectively (95% CI,

267 gs in which MRSA was prevalent, trimethoprim-sulfamethoxazole treatment resulted in a higher cure rat

268 d antibiotics (sulfadiazine, sulfamethazine, sulfamethoxazole, trimethoprim) and incubated with flood

269 ), Imipenem (n=2235), Ofloxacin (n=3117) and Sulfamethoxazole-Trimethoprim (n=3544).

270 t to most antibiotics, with the exception of sulfamethoxazole-trimethoprim (SXT).

271 Retrospective single-center study comparing sulfamethoxazole-trimethoprim 800/160 mg (SMZ/TMP) daily

272 e genes and mobile genetic elements, such as sulfamethoxazole-trimethoprim constins and class I integ

273 initial management of chronic diarrhea with sulfamethoxazole-trimethoprim in HIV-1-infected persons

274 nosis of furunculosis was made, and Bactrim (sulfamethoxazole-trimethoprim; AR Scientific, Philadelph

275 13.82), ampicillin (6.02; 95%CI: 3.31-8.73), sulfamethoxazole/ trimethoprim (4.49; 95%CI: 2.42-6.56),

276 %; tobramycin, 90.6%; gentamicin, 80.6%; and sulfamethoxazole/trimethoprim, 59.4%.

277 lowing: vancomycin, 100%; gentamicin, 88.0%; sulfamethoxazole/trimethoprim, 77.5%; levofloxacin, 58.5

278 Filgrastim, sulfamethoxazole/trimethoprim, and acyclovir were admini

279 romycin, but CA-MRSA was more susceptible to sulfamethoxazole/trimethoprim.

280 oxine-pyrimethamine (SP), daily trimethoprim-sulfamethoxazole (TS), or monthly dihydroartemisinin-pip

281 ve to minocycline, doxycycline, trimethoprim-sulfamethoxazole, vancomycin, teicoplanin, and linezolid

282 isolates that were resistant to trimethoprim-sulfamethoxazole was 63% in the prophylaxis group and 19

283 Trimethoprim-sulfamethoxazole was associated with slightly more gastr

284 ed antibiotic at the beginning, trimethoprim-sulfamethoxazole was most frequently prescribed by the e

285 Trimethoprim-sulfamethoxazole was superior to placebo with respect to

286 ed antibiotic at the beginning, trimethoprim-sulfamethoxazole was the most frequently prescribed anti

287 cin, meropenem, tobramycin, and trimethoprim-sulfamethoxazole were comparable for the two methods: th

288 ical center, even though no tetracycline and sulfamethoxazole were consumed, the highest occurrences

289 , tetracycline, tilmicosin, and trimethoprim-sulfamethoxazole were determined for each isolate, as we

290 w form of carbamazepine and two new forms of sulfamethoxazole were discovered; in these cases, single

291 ide, 4-nitroso sulfamethoxazole, and 4-nitro sulfamethoxazole were irradiated under various light sou

292 cale system (t1/2 < 0.5 d), trimethoprim and sulfamethoxazole were transformed more slowly (t1/2 appr

293 persistent antibiotic compounds (ofloxacin, sulfamethoxazole) were found, but they did not correspon

294 veral compounds, including carbamazepine and sulfamethoxazole, were detected throughout the study rea

295 ed by subinhibitory levels of the antifolate sulfamethoxazole, which is used to treat infections incl

296 discaviarum were susceptible to trimethoprim-sulfamethoxazole, while 8% of N. farcinica isolates were

297 Children not receiving trimethoprim-sulfamethoxazole with capillary whole blood concentratio

298 The reactivity of sulfamethoxazole with the reactive species produced when

299 ylaxis most frequently involves trimethoprim-sulfamethoxazole, with second-line therapies, including

300 termine whether cephalexin plus trimethoprim-sulfamethoxazole yields a higher clinical cure rate of u